The Food and Drug Administration has today approved lecanemab, a new drug for Alzheimer's disease, for use across the US.

Alzheimer's Society, study participant Eric Deeson and Sir Prof John Hardy comment on the disappointing clinical trial results for Alzheimer's drug gantenerumab.

Dr Richard Oakley, Associate Director of Research at Alzheimer’s Society, comments on news surrounding breakthrough Alzheimer's drug lecanemab.

Yesterday (27 September 2022), Eisai Co. Ltd. and Biogen announced top-line results for a major trial on the drug lecanemab in slowing down the progress of Alzheimer’s disease. Alzheimer's Society comments on this Alzheimer’s progression drug hope.

The European Medicines Agency (EMA) has recommended that aducanumab, marketed as Aduhelm, is not approved for use across the EU. The drug was previously approved for use in the US by the Food and Drug Administration (FDA) on 7 June 2021.